Department of Health Behavior and Health Systems, School of Public Health, University of North Texas Health Science Center, 3500 Camp Bowie Blvd., Fort Worth, TX, 76107, USA.
Department of Biostatistics and Epidemiology, School of Public Health, University of North Texas Health Science Center, Fort Worth, TX, 76107, USA.
J Community Health. 2021 Oct;46(5):893-902. doi: 10.1007/s10900-021-00968-3. Epub 2021 Feb 13.
HPV vaccine is recommended for 27-45 year olds in the U.S. based on a shared clinical decision. This study examined knowledge, attitudes, and beliefs of adults 27-45 years old and the association with the likelihood of asking a healthcare provider about the HPV vaccine and the likelihood of getting the HPV vaccine. We conducted a cross-sectional survey of U.S. adults aged 27-45 years between April-May 2020 (n = 691). Primary outcomes were likelihood of asking their provider about the HPV vaccine and likelihood of getting the HPV vaccine. Demographic variables, knowledge, attitudes, and beliefs were covariates. Adjusted models were estimated for each outcome variable with a Poisson distribution and log function. More than half (55.7%) were likely to ask their provider about the HPV vaccine, but less than half (42.9%) were likely to get the HPV vaccine. Likelihood of asking their provider about the HPV vaccine was significantly associated with perceived likelihood of benefitting from the vaccine (aOR = 2.45; 95%CI = 1.69-3.57). Likelihood of receiving the vaccine was associated with attitudes (aOR = 1.04; 95%CI = 1.01-1.07), perceived effectiveness against HPV infection (aOR = 4.03; 95%CI = 1.20-13.53), and perceived likelihood of benefitting from the vaccine (aOR = 4.31; 95%CI = 2.64-7.03). Our findings suggest increasing positive attitudes, perceived effectiveness against infection, and perceived likelihood of benefitting from the vaccination are important factors to address when facilitating a shared clinical decision for HPV vaccination. Understanding factors associated with likelihood of discussing and receiving the HPV vaccine among people aged 27-45 years is important to successfully implement the guidelines for shared clinical decision-making.
HPV 疫苗在美国推荐用于 27-45 岁人群,这是基于共同的临床决策。本研究调查了 27-45 岁成年人的知识、态度和信念,以及与向医疗保健提供者询问 HPV 疫苗的可能性和接种 HPV 疫苗的可能性之间的关联。我们于 2020 年 4 月至 5 月期间对美国 27-45 岁成年人进行了横断面调查(n=691)。主要结局是询问提供者 HPV 疫苗的可能性和接种 HPV 疫苗的可能性。人口统计学变量、知识、态度和信念为协变量。使用泊松分布和对数函数对每个结局变量进行调整模型估计。超过一半(55.7%)的人可能会询问提供者 HPV 疫苗,而不到一半(42.9%)的人可能会接种 HPV 疫苗。询问提供者 HPV 疫苗的可能性与认为从疫苗中获益的可能性显著相关(aOR=2.45;95%CI=1.69-3.57)。接种疫苗的可能性与态度(aOR=1.04;95%CI=1.01-1.07)、针对 HPV 感染的有效性(aOR=4.03;95%CI=1.20-13.53)和认为从疫苗中获益的可能性(aOR=4.31;95%CI=2.64-7.03)相关。我们的研究结果表明,增加积极的态度、针对感染的有效性和从疫苗接种中获益的可能性是促进 HPV 疫苗接种共同临床决策的重要因素。了解 27-45 岁人群中讨论和接种 HPV 疫苗的可能性相关因素对于成功实施共同临床决策指南非常重要。